Lubiprostone added to maintenance therapy to prevent colorectal cancer recurrence
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding lubiprostone (a medication often used for constipation) to your usual maintenance therapy can help prevent colorectal cancer from coming back after surgery for cancer that has spread to the lining of the abdomen. The goal is to improve the chance of staying cancer-free.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colon or rectal cancer (adenocarcinoma) that is confirmed by biopsy or surgery.
- Your cancer is a type called 'pMMR' or 'MSS' (not the MSI-H type).
- You had surgery (cytoreductive surgery) that removed all visible cancer, or left only minimal disease.
- Your cancer has not spread to areas outside your abdomen.
- You are in good general health (able to do daily activities) with no major organ problems.
- You do not have a specific gene mutation called BRAF V600E.
- You have not had another cancer in the last 5 years (except some skin or early-stage cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
This trial tests whether adding a probiotic (a beneficial bacteria) to a standard chemo-immunotherapy combination can improve outcomes for people with metastatic colorectal cancer that hasn't responded to earlier treatments.
This Phase 3 trial tests whether an added “maintenance” treatment after liver surgery can help prevent colorectal cancer from coming back. It is only for people whose blood test (ctDNA) still shows signs of cancer after their operation.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This trial tests a new approach for advanced low rectal cancer. You'll receive a combination of chemotherapy, immunotherapy, and radiation before surgery, which may help shrink the tumor and make surgery easier.
This trial tests a combination of three drugs—chemotherapy plus two targeted therapies—as a first treatment for colorectal cancer that cannot be surgically removed. The goal is to shrink tumors enough to allow surgery later, potentially improving outcomes.
Hear when a new Peritoneal (Metastatic) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.